Sanuwave Health (NASDAQ:SNWV) Downgraded to "Hold" Rating by Wall Street Zen

Key Points

• Analysts at Wall Street Zen have downgraded Sanuwave Health's stock from a "buy" to a "hold" rating.
• Sanuwave Health reported a quarterly earnings beat, with $0.01 earnings per share, surpassing estimates of ($0.09).
• The company's current market cap stands at $298.92 million, with shares trading at $34.88 after reaching a high of $46.58 in the past year.

Sanuwave Health (NASDAQ:SNWV - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Saturday.

A number of other equities analysts have also recently commented on the stock. Northland Securities initiated coverage on shares of Sanuwave Health in a research report on Wednesday, September 3rd. They issued an "outperform" rating and a $55.00 target price on the stock. Northland Capmk upgraded shares of Sanuwave Health to a "strong-buy" rating in a research report on Wednesday, September 3rd. Finally, Roth Capital lifted their target price on shares of Sanuwave Health from $54.00 to $55.00 and gave the stock a "buy" rating in a research report on Friday, August 22nd. One equities research analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $55.00.

Sanuwave Health Trading Down 0.1%

Shares of Sanuwave Health stock traded down $0.04 on Friday, hitting $35.26. 3,742 shares of the company traded hands, compared to its average volume of 50,706. The company's 50-day simple moving average is $37.88. The company has a market capitalization of $302.18 million, a P/E ratio of -4.27 and a beta of 1.39. Sanuwave Health has a 12-month low of $5.63 and a 12-month high of $46.58.

Sanuwave Health (NASDAQ:SNWV - Get Free Report) last posted its quarterly earnings data on Friday, August 8th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.10. The company had revenue of $10.16 million for the quarter, compared to analysts' expectations of $10.14 million. Sanuwave Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of SNWV. Strategic Investment Solutions Inc. IL purchased a new position in Sanuwave Health in the first quarter worth about $47,000. Solas Capital Management LLC purchased a new position in Sanuwave Health in the first quarter worth about $20,658,000. AWM Investment Company Inc. purchased a new position in Sanuwave Health in the first quarter worth about $18,153,000. Goldman Sachs Group Inc. purchased a new position in Sanuwave Health in the first quarter worth about $337,000. Finally, Evernest Financial Advisors LLC purchased a new position in Sanuwave Health in the second quarter worth about $823,000. 42.53% of the stock is owned by hedge funds and other institutional investors.

Sanuwave Health Company Profile

SANUWAVE Health, Inc, a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures.